MB
MPM BioImpact Portfolio holdings
AUM
$1.29B
1-Year Est. Return
141.72%
This Fund
S&P 500
1 Year Est. Return
+141.72%
AUM
$874M
AUM Growth
+$263M
(+43%)
Holding
55
Top Buys
| 1 | +$53.3M | |
| 2 | +$45.7M | |
| 3 | +$34.2M | |
| 4 |
Corvus Pharmaceuticals
CRVS
|
+$21.6M |
| 5 |
UroGen Pharma
URGN
|
+$17.5M |
Top Sells
| 1 | +$33.1M | |
| 2 | +$25.3M | |
| 3 | +$17.8M | |
| 4 |
Alkermes
ALKS
|
+$16.5M |
| 5 |
Vera Therapeutics
VERA
|
+$16.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Design Therapeutics
DSGN
$655M
| – | – |
-555,187
|
|
||
52
Compass Therapeutics
CMPX
$429M
| – | – |
-5,075,970
|
|
||
53
Assembly Biosciences
ASMB
$548M
| – | – |
-39,665
|
|
||
|
54
Alkermes
ALKS
$7.03B
| – | – |
-549,262
|
|
||
55
Akebia Therapeutics
AKBA
$274M
| – | – |
-2,889,125
|
|